他汀类药物与曲美他嗪联用治疗心绞痛的疗效研究

Efficacy research of statins combined with Trimetazidine in the treatment of angina pectoris

目的探讨他汀类药物与曲美他嗪联用治疗心绞痛的疗效。方法 80例心绞痛患者纳入研究,随机分为对照组和实验组,各40例。对照组患者给予辛伐他汀治疗,实验组患者给予辛伐他汀联合曲美他嗪治疗。比较两组患者的治疗效果、心功能水平、实验室指标以及不良反应发生情况。结果实验组治疗总有效率为95.00%,高于对照组的77.50%,差异具有统计学意义(P<0.05)。实验组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)分别为(51.26±5.32)mm、(37.24±9.13)mm、(45.26±6.28)%,均明显优于对照组的(56.76±7.62)mm、(42.28±9.22)mm、(41.47±8.07)%,差异具有统计学意义(P<0.05)。实验组甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)以及低密度脂蛋白胆固醇(LDL-C)分别为(3.33±1.85)、(4.11±1.52)、(2.68±1.22)、(2.71±1.15)mmol/L,均明显优于对照组的(5.04±2.51)、(5.61±0.76)、(1.72±0.68)、(4.17±1.49)mmol/L,差异具有统计学意义(P<0.05)。实验组不良反应发生率为7.50%,低于对照组的25.00%,差异具有统计学意义(P<0.05)。结论采用辛伐他汀联合曲美他嗪治疗心绞痛患者,可以显著提高患者的治疗效果,同时改善患者的心功能水平和实验室指标,减少不良反应的发生,值得社区采纳。

Objective To investigate the efficacy of statins combined with Trimetazidine in the treatment of angina pectoris. Methods A total of 80 patients with angina pectoris were included in the study and randomly divided into control group and experimental group, 40 cases in each group. Patients in the control group were treated with Simvastatin, patients in the experimental group were treated with Simvastatin combined with Trimetazidine. The therapeutic effect, cardiac function, laboratory indicators and adverse reactions between the two groups were observed. Results The total effective rate of the experimental group was 95.00%, which was significantly higher than 77.50% of the control group, the difference was statistically significant（P〈0.05）. The left ventricular end-diastolic diameter（LVEDD）, left ventricular end-systolic diameter（LVESD） and left ventricular ejection fraction（LVEF） of the experimental group were（51.26±5.32） mm,（37.24±9.13） mm and（45.26±6.28）% respectively, which were significantly better than（56.76±7.62） mm,（42.28±9.22） mm and（41.47±8.07）% of the control group, the differences were statistically significant（P〈0.05）. The triglyceride（TG）, total cholesterol（TC）, high density lipoprotein cholesterol（HDL-C） and low density lipoprotein cholesterol（LDL-C） of the experimental group were（3.33±1.85） mmol/L,（4.11±1.52） mmol/L,（2.68±1.22） mmol/L and（2.71± 1.15） mmol/L respectively, which were significantly better than（5.04±2.51） mmol/L,（5.61±0.76） mmol/L,（1.72±0.68） mmol/L and（4.17±1.49） mmol/L of the control group, the differences were statistically significant（P〈0.05）. The incidence of adverse reactions in the experimental group was 7.50%, which was significantly lower than 25.00% in the control group, the difference was statistically significant（P〈0.05）. Conclusion The application of Simvastatin combined with Trimetazidine in the treatment of angina pectoris patients can significantly improve the efficacy of patients, while improving the level of cardiac function and laboratory indicators, reduce the incidence of adverse reactions, is worthy of community adoption.